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Pregnancy in a patient with adrenocortical carcinoma
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Ciąża u pacjentki z rakiem kory nadnerczy w trakcie leczenia mitotanem
— opis przypadku
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Abstract
We present the case of a female patient with virilising adrenocortical carcinoma treated surgically who conceived during adjuvant treat-
ment with mitotane. We discuss the frequently erroneous routine treatment with oral hormonal contraception without thorough differen-
tial diagnosis in female patients with oligo-/amenorrhea and subsequent delay in the proper diagnosis of adrenocortical carcinoma.
(Pol J Endocrinol 2011; 62 (2): 186–188)
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Streszczenie
W pracy przedstawiono młodą pacjentkę z wirylizującym rakiem kory nadnerczy leczonym operacyjnie, która zaszła w ciążę w trakcie
terapii uzupełniającej mitotanem. Omówiono jednocześnie często błędne, rutynowe leczenie tabletkami antykoncepcyjnymi pacjentek z
niezdiagnozowanymi zaburzeniami miesiączkowania o typie oligo-/amenorrhea i wynikające z tego opóźnienie rozpoznania raka kory
nadnerczy. (Endokrynol Pol 2011; 62 (2): 186–188)
Słowa kluczowe: rak kory nadnerczy, mitotan, ciąża
Introduction
Primary adrenocortical carcinomas (ACC) are very rare,
with an incidence of approximately 1-2 per million pop-
ulation per year [1]. In Poland, in a group of 1,790 pa-
tients with incidentally-found adrenal tumours ob-
served in one centre, primary adrenal cancers were
found in 7.5% of cases [2]. ACC may be found inciden-
tally or may manifest as an abdominal mass or a char-
acteristic syndrome of hormonal oversecretion. Carci-
nomas with excessive hormonal production occur in up
to 60% of patients, mostly women, and manifest as
Cushing’s syndrome and/or virilisation [3]. ACCs can
develop at any age, but are usually diagnosed before
the age of five or between the ages of 30 and 50 [1].
ACCs used to be considered as extremely aggressive
tumours, with prognosis in the adult population worse
than compared to that of children. Nowadays, survival
may be higher than previously thought. The optimal
treatment is complete surgical resection [4]; but because
occult micrometastases are present at the time of initial
presentation and surgery [5], additional treatment with
Mitotane alone, or sometimes in combination with oth-
er cytotoxic agents, is recommended by many authors
[1, 4, 7].
A case report
A female patient, aged 26, was admitted to the Depart-
ment of Endocrinology for the first time in 2008 because
of suspected adrenocortical carcinoma. At the age of 24,
she had had secondary amenorrhea for a year with
symptoms of hyperandrogenism, manifesting mostly
as rapid development of hirsutism. After consultation
with a gynaecologist, oral contraceptives were pre-
scribed, which the patient took for another year until
a severe abdominal pain occurred and an ultrasound
examination was performed. A huge abdominal tumour
was discovered. Computer tomography confirmed the
presence of a tumour measuring 170 × 110 × 150 mm,
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which may have originated from the left adrenal. Hor-
monal assessment revealed markedly increased DHEAS
concentration (> 1000 mg/dL), with low normal corti-
sol level (259.4, 137 nmol/L). Stimulatory tests to exclude
adrenal gland insufficiency were not performed at that
time. Left adrenalectomy was performed and adreno-
cortical cancer (stage II, [6]) was confirmed with the
expression of Ki67+ in 1% of cells. Six weeks later, hor-
monal analysis showed normalisation of the androgens
(DHEAS 88.55 mg/dL, androstendion 0.7 ng/mL, 17aOH
progesterone 1.3 ng/mL, free testosterone 1.1 pg/mL).
Imaging studies did not show local recurrence or me-
tastases. Mitotane treatment was started and concen-
tration of the androgens further decreased. The patient
began to menstruate spontaneously, but irregularly,
hence progestins were recommended for days 16–25 of
each cycle. The patient was informed of the necessity
of non-hormonal contraception.
Fourteen months later, the patient conceived and
a twin pregnancy was confirmed. The patient and her
partner were informed of the possible teratogenic
effect of Mitotane, but they decided to continue the
pregnancy. The serum concentration of the drug was
12.5 mg/mL, slightly below the therapeutic range (reco-
mmended therapeutic range: 14–20 mg/mL).
The course of the pregnancy was complicated by the
risk of pre-term delivery in the 6th week of gestation,
hence progesterone was prescribed. Unfortunately, in
the 10th week of gestation, missed labour was diagnosed
and abortion was induced. Evaluation of the patient
performed one and six months later did not reveal pro-
gression of the ACC.
Discussion
The case presented here is extremely unusual. Although
ACC can occur at any age, its manifestation in the third
decade is rare.
Mitotane (Lysodren, o,p’-DDD, a congener of the
pesticide dichloro-diphenyl-trichloroethane [DDT]), an
adrenolytic and cytotoxic agent, has been used for
50 years in the treatment of adrenocortical carcinoma.
The adrenolytic effect of the drug depends on its metabolic
activation due to conversion to o,p’-DDA and o,p’-DDE.
It affects mitochondria in adrenal cortical cells, where it
inhibits pregnenolone and cortisol synthesis. The drug
also alters the peripheral metabolism of steroids [7].
Toxic effect may vary depending on the tissue, i.e. the
zona glomerulosa of the adrenals is more resistant and
aldosterone deficiency may occur later than hypocorti-
solemia [8]. The gonadal toxicity of Mitotane is un-
known. Some authors report anti-oestrogenic effects [9].
In our patient, the excessive concentration of androgens
prior to surgery had suppressed ovarian function for at
least two years. Adrenalectomy and the subsequent
decrease in androgens resulted in the spontaneous nor-
malisation of ovarian function. Even concomitant treat-
ment with Mitotane did not further impair ovarian func-
tion. During the follow-up prior to pregnancy, normal
ovarian function had been observed by ovulatory concen-
trations of LH, FSH and E2 (42.79 mU/mL, 6.75 mU/mL,
257.6 pg/mL, respectively) and ultrasonography.
Mitotane is a category C pregnancy risk factor, hence
contraception is suggested for female patients of repro-
ductive age [8]. However, we did not suggest oral con-
traception shortly after the adrenalectomy, because the
patient did not have a sexual partner at that time, and
we chose to wait for the androgen concentration to de-
crease and spontaneous menstruation to resume. Lat-
er, oral contraception was prescribed, but the patient
did not take it because of negative past experiences and
the cost. Although we did prescribe it, we still had
doubts if hormonal contraception would be effective
and safe. Mitotan has a hepatotoxic effect and, as men-
tioned above, it influences the peripheral metabolism of
steroids and changes hepatic production of proteins. No
studies have been performed on the interaction of both
drugs and contraceptive effectiveness if taken together.
After pregnancy was confirmed, the initial thought
was to cease treatment. But Mitotane has a long half-
life, which is mainly due to its accumulation in adipose
tissue and it is detected in blood even several months
after the patient has ceased to take it. Thus during the
critical period of organogenesis, our patient would still
have high blood concentration of the drug, and neither
our patient nor the foetus would have benefited if treat-
ment had been stopped. On the other hand, pregnan-
cy is a state of increased concentration of various growth
factors that promote the development of the foetus [10].
Thus, fearing ACC progression, we decided to contin-
ue the treatment.
Unfortunately, a pathological examination was not
performed following the abortion and we do not have
data on possible foetal tissue damage.
In the past, the prognosis for patients with ACC was
extremely poor. Nowadays, we have reports of the long-
term survival of some patients and even successful preg-
nancies have been reported [11, 12]. We plan to treat
the described patient with Mitotane for approximately
five years and, if there are no recurrences, to cease treat-
ment. After approximately a year, we plan to check the
Mitotane serum concentration, and if it is no longer
detectable we can then tell the patient that pregnancy
is now possible.
Oral contraception has been used too often as the
first line approach to restore monthly vaginal bleeding
in patients with oligo-/amenorrhea instead of carrying
out a thorough examination and making a diagnosis.
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One should keep in mind that the evaluation of such
patients requires the exclusion of hyperprolactinemia,
abnormal thyroid function, PCOS, hyperinsulinemia,
adrenal hyperplasia and androgen-secreting tumours
[13]. In our opinion, which is also based on other tragic
cases of women treated in our Department, differential
diagnosis should focus above all on excluding adrenal
or ovarian carcinomas, at least by performing an ultra-
sound examination, as these diseases have the highest
mortality, and early diagnosis and proper treatment
may save lives.
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